Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8341 to 8355 of 8905 results

  1. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  2. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  3. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Withdrawn advice

  4. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  5. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

    Withdrawn advice

  6. Lubiprostone for treating chronic idiopathic constipation (TA318)

    This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).

    Withdrawn guidance

  7. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)

    This guidance has been updated and replaced by NICE technology appraisal guidance 527.

    Withdrawn guidance

  8. Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)

    This guidance has been updated and replaced by NICE technology appraisal guidance 604.

    Withdrawn guidance

  9. Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309)

    This guidance has been updated and replaced by NICE technology appraisal guidance 402.

    Withdrawn guidance

  10. The clinical effectiveness and cost effectiveness of sibutramine for obesity (TA31)

    This guidance has been replaced by NICE guideline CG43. 

    Withdrawn guidance

  11. Ustekinumab for treating active psoriatic arthritis (TA313)

    This guidance has been updated and replaced by NICE technology appraisal guidance 340.

    Withdrawn guidance

  12. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.    

    Withdrawn guidance

  13. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

    Withdrawn guidance

  14. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)

    This guidance has been updated and replaced by NICE technology appraisal guidance 386.

    Withdrawn guidance

  15. Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)

    The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.

    Withdrawn guidance